卡铂联合培美曲塞可显著改善晚期NSCLC患者生存情况.pdf

Published Ahead of Print on June 17, 2013 as 10.1200/JCO.2012.48.1911 The latest version is at /cgi/doi/10.1200/JCO.2012.48.1911 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2 Mauro Zukin, Carlos H. Barrios, Jose Rodrigues Pereira, Ronaldo De Albuquerque Ribeiro, Carlos Augusto de Mendonc¸a Beato, Yeni Neron do Nascimento, Andre Murad, Fabio A. Franke, Maristela Precivale, Luiz Henrique de Lima Araujo, Clarissa Serodio Da Rocha Baldotto, Fernando Meton Vieira, Isabele A. Small, Carlos G. Ferreira, and Rogerio C. Lilenbaum Processed as a Rapid Communication manuscript Mauro Zukin, Luiz Henrique de Lima A B S T R A C T Araujo, Clarissa Serodio Da Rocha Baldotto, Fernando Meton Vieira, Isabele A. Small, and Carlos G. Ferreira, Purpose Instituto Nacional do Cancer, Rio de To compare single-agent pemetrexed (P) versus the combination of carboplatin and pemetrexed Janeiro; Carlos H. Barrios, Pontifícia (CP) in first-line therapy for patients with advanced non–small-cell lung cancer (NSCLC) with an Universidade Cato´lica do Rio Grande do Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. Sul, P